Top

Published in:

01-04-2016 | Original Article

miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6

Authors: Weiwei Shan, Jun Li, Yang Bai, Xin Lu

Published in: Tumor Biology | Issue 4/2016

Abstract

This study aimed to explore the role of miR-339-5p in ovarian cancer. The expression of miR-339-5p in seven ovarian cancer cell lines (Hey, SKOV3, OVCAR5, SKOV3-IP, A2780, CAOV3, and OVCA433) was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The miR-339-5p mimic and inhibitor were used to regulate its expression. Migration, invasion, and proliferation were examined. A bioinformatics analysis was used to predict targets, and a dual-luciferase reporter system was applied for validation, along with Western blot verification. Additionally, the association of miR-339-5p and its target genes with ovarian cancer was analyzed based on The Cancer Genome Atlas (TCGA) database. OVCAR5 and SKOV3 had the highest and lowest miR-339-5p expression, respectively. Inhibition of miR-339-5p expression increased the migration and invasion of OVCAR5 cells, while in SKOV3 cells, upregulated miR-339-5p attenuated the migration and invasion ability. Modulation of miR-339-5p had no effect on proliferation. The genes nucleus accumbens associated 1(BEN and BTB (POZ) domain containing) (NACC1) and B cell lymphoma-6 (bcl6) were validated to be targets of miR-339-5p. Clinically, patients with a high expression of NACC1 had a high risk in the survival analysis. miR-339-5p inhibits migration and invasion in ovarian cancer by targeting NACC1 and BCL6. miR-339-5p may be a biomarker of metastasis in ovarian cancer; NACC1 had a predictive value for ovarian cancer progression.

Available only for authorised users

Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309:C444–56.CrossRefPubMedPubMedCentral

Oktay K, Turan V, Titus S, Stobezki R, Liu L. BRCA mutations, DNA repair deficiency, and ovarian aging. Biol Reprod. 2015;93:67.CrossRefPubMedPubMedCentral

Torres A, Torres K, Maciejewski R, Harvey WH. MicroRNAs and their role in gynecological tumors. Med Res Rev. 2011;31:895–923.CrossRefPubMed

Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.CrossRefPubMed

Cui J, Li D, Zhang W, Shen L, Xu X. Bioinformatics analyses combined microarray identify the deregulated microRNAs in oral cancer. Oncol Lett. 2014;8:218–22.PubMedPubMedCentral

Guo WG, Zhang Y, Ge D, Zhang YX, Lu CL, Wang Q, et al. Bioinformatics analyses combined microarray identify the desregulated microRNAs in lung cancer. Eur Rev Med Pharmacol Sci. 2013;17:1509–16.PubMed

Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, Melen GJ, Sanchez L, Ligero G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol. 2008;28:6609–19.CrossRefPubMedPubMedCentral

Deng G, Sui G. Noncoding RNA in oncogenesis: a new era of identifying key players. Int J Mol Sci. 2013;14:18319–49.CrossRefPubMedPubMedCentral

Su JL, Chen PS, Johansson G, Kuo ML. Function and regulation of let-7 family microRNAs. MicroRNA. 2012;1:34–9.CrossRefPubMed

10.

Zhang CL, Li Z, Liu YP, Wu Y, Qu XJ. Prognostic role of the let-7 family in various carcinomas: a meta-analysis update. J BUON. 2015;20:631–44.PubMed

11.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed

12.

Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197–208.CrossRefPubMed

13.

Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241.CrossRefPubMedPubMedCentral

14.

Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, et al. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010;10:542.CrossRefPubMedPubMedCentral

15.

Zhou C, Liu G, Wang L, Lu Y, Yuan L, Zheng L, et al. MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1. PLoS One. 2013;8:e63142.CrossRefPubMedPubMedCentral

16.

Li Y, Zhao W, Bao P, Li C, Ma XQ, Li Y, et al. miR-339-5p inhibits cell migration and invasion and may be associated with the tumor-node-metastasis staging and lymph node metastasis of non-small cell lung cancer. Oncol Lett. 2014;8:719–25.PubMedPubMedCentral

17.

Wang YL, Chen CM, Wang XM, Wang L. Effects of miR-339-5p on invasion and prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2015.

18.

Rani S, Gately K, Crown J, O’Byrne K, O’Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther. 2013;14:1104–12.CrossRefPubMedPubMedCentral

19.

Jansson MD, Damas ND, Lees M, Jacobsen A, Lund AH. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2. Oncogene. 2015;34:1908–18.CrossRefPubMed

20.

Liu DZ, Ander BP, Tian Y, Stamova B, Jickling GC, Davis RR, et al. Integrated analysis of mRNA and microRNA expression in mature neurons, neural progenitor cells and neuroblastoma cells. Gene. 2012;495:120–7.CrossRefPubMed

21.

Ishikawa M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, et al. NAC1, a potential stem cell pluripotency factor expression in normal endometrium, endometrial hyperplasia and endometrial carcinoma. Int J Oncol. 2010;36:1097–103.PubMed

22.

Shih Ie M, Davidson B. Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 2009;5:1641–57.CrossRefPubMed

23.

Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Katagiri A, et al. Biological role and prognostic significance of NAC1 in ovarian cancer. Gynecol Oncol. 2010;119:469–78.CrossRefPubMed

24.

Shih Ie M, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol. 2011;24:638–45.CrossRefPubMed

25.

Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, et al. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A. 2006;103:18739–44.CrossRefPubMedPubMedCentral

26.

Gao M, Wu RC, Herlinger AL, Yap K, Kim JW, Wang TL, et al. Identification of the NAC1-regulated genes in ovarian cancer. Am J Pathol. 2014;184:133–40.CrossRefPubMedPubMedCentral

27.

Zhang Y, Cheng Y, Ren X, Hori T, Huber-Keener KJ, Zhang L, et al. Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis. Cancer Res. 2012;72:4262–75.CrossRefPubMedPubMedCentral

28.

Jinawath N, Vasoontara C, Yap KL, Thiaville MM, Nakayama K, Wang TL, et al. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene. 2009;28:1941–8.CrossRefPubMedPubMedCentral

29.

Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL, Wu H, et al. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene. 2012;31:1055–64.CrossRefPubMed

30.

Zhang Y, Yang JW, Ren X, Yang JM. NAC1 and HMGB1 enter a partnership for manipulating autophagy. Autophagy. 2011;7:1557–8.CrossRefPubMedPubMedCentral

31.

Nakayama K, Nakayama N, Miyazaki K. Development of a novel ovarian cancer molecular target therapy against cancer-related transcriptional factor, NAC1. J Obstet Gynaecol Res. 2013;39:18–25.CrossRefPubMed

32.

Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, et al. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett. 2015;365:190–200.CrossRefPubMed

33.

Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol. 2015;39:1132–9.CrossRefPubMed

34.

Deucher AM, Qi Z, Yu J, George TI, Etzell JE. BCL6 expression correlates with the t (1;19) translocation in B-lymphoblastic leukemia. Am J Clin Pathol. 2015;143:547–57.CrossRefPubMed

35.

Liang PI, Li CF, Chen LT, Sun DP, Chen TJ, Hsing CH, et al. BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma. Tumour Biol. 2014;35:1417–26.CrossRefPubMed

36.

Wang YQ, Xu MD, Weng WW, Wei P, Yang YS, Du X. BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer. Am J Cancer Res. 2015;5:255–66.PubMed

37.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, et al. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 2015;34:1073–82.CrossRefPubMed

Title: miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6
Authors: Weiwei Shan
Jun Li
Yang Bai
Xin Lu
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4390-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors

An association analysis between mitochondrial DNA content, G10398A polymorphism, HPV infection, and the prognosis of cervical cancer in the Chinese Han population

RETRACTED ARTICLE: MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1

IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer

Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas

The c.*229C > T gene polymorphism in 3′UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer